Published in Curr Top Microbiol Immunol on January 01, 2010
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov (2014) 2.55
Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene (2012) 1.95
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther (2013) 1.44
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood (2012) 1.25
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One (2011) 1.05
Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget (2014) 0.98
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis (2014) 0.93
The stemness phenotype model. ISRN Oncol (2012) 0.88
ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models. Mol Cancer (2016) 0.86
Strategies for isolating and enriching cancer stem cells: well begun is half done. Stem Cells Dev (2013) 0.84
Distinct metabolic responses of an ovarian cancer stem cell line. BMC Syst Biol (2014) 0.84
The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Rev (2015) 0.84
The cardiac hypoxic niche: emerging role of hypoxic microenvironment in cardiac progenitors. Cardiovasc Diagn Ther (2012) 0.83
Mitochondria as therapeutic targets for cancer stem cells. World J Stem Cells (2015) 0.82
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids. PLoS One (2014) 0.82
Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells. Cell Death Dis (2013) 0.81
Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther (2014) 0.81
Hitting the Bull's-Eye in Metastatic Cancers-NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death. Pharmaceuticals (Basel) (2015) 0.79
Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma. Angiol Open Access (2013) 0.79
DEspR roles in tumor vasculo-angiogenesis, invasiveness, CSC-survival and anoikis resistance: a 'common receptor coordinator' paradigm. PLoS One (2014) 0.79
Oxidative stress and the homeodynamics of iron metabolism. Biomolecules (2015) 0.79
Hypoxia-responsive miR-210 promotes self-renewal capacity of colon tumor-initiating cells by repressing ISCU and by inducing lactate production. Oncotarget (2016) 0.76
The emerging roles of Oct4 in tumor-initiating cells. Am J Physiol Cell Physiol (2015) 0.76
Estradiol, TGF-β1 and hypoxia promote breast cancer stemness and EMT-mediated breast cancer migration. Oncol Lett (2016) 0.75
MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget (2017) 0.75
HAF drives the switch of HIF-1α to HIF-2α by activating the NF-κB pathway, leading to malignant behavior of T24 bladder cancer cells. Int J Oncol (2013) 0.75
Hypoxia is no hype: Perspectives across Phylogeny, Stem Cell differentiation & Geochemistry. J Stem Cells Regen Med (2015) 0.75
The effects of hypoxia on the stemness properties of human dental pulp stem cells (DPSCs). Sci Rep (2016) 0.75
Notch signaling regulates metabolic heterogeneity in glioblastoma stem cells. Oncotarget (2017) 0.75
Multiplexed RNAi therapy against brain tumor-initiating cells via lipopolymeric nanoparticle infusion delays glioblastoma progression. Proc Natl Acad Sci U S A (2017) 0.75
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res (2007) 9.21
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell (2004) 3.63
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
Recent advances in the treatment of malignant astrocytoma. J Clin Oncol (2006) 2.55
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci (2013) 2.30
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (2009) 1.97
Molecularly targeted therapy for malignant glioma. Cancer (2007) 1.96
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth. Mol Carcinog (2007) 1.74
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Biology of glioma cancer stem cells. Mol Cells (2009) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
Informed consent in pediatric surgery: Do parents understand the risks? Arch Otolaryngol Head Neck Surg (2010) 1.55
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Deubiquitylase HAUSP stabilizes REST and promotes maintenance of neural progenitor cells. Nat Cell Biol (2011) 1.49
Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell (2011) 1.49
New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther (2006) 1.47
Elevated invasive potential of glioblastoma stem cells. Biochem Biophys Res Commun (2011) 1.39
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res (2008) 1.35
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 1.35
Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem (2009) 1.33
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res (2004) 1.33
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Designer therapies for glioblastoma multiforme. Ann N Y Acad Sci (2008) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol (2010) 1.26
Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 1.21
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer (2005) 1.21
Receptor channel TRPC6 is a key mediator of Notch-driven glioblastoma growth and invasiveness. Cancer Res (2009) 1.18
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12
L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J (2011) 1.10
Loss of phosphatase and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res (2005) 1.10
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol (2007) 1.10
Diagnosis and treatment of high-grade astrocytoma. Neurol Clin (2007) 1.08
β-Catenin/POU5F1/SOX2 transcription factor complex mediates IGF-I receptor signaling and predicts poor prognosis in lung adenocarcinoma. Cancer Res (2013) 1.08
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer (2005) 1.07
miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A (2013) 1.06
Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells. Endocr Relat Cancer (2013) 1.06
EGFR mutations and sensitivity to gefitinib. N Engl J Med (2004) 1.05
The zinc finger transcription factor ZFX is required for maintaining the tumorigenic potential of glioblastoma stem cells. Stem Cells (2014) 1.05
Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem (2004) 1.04
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer (2010) 1.03
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol (2011) 1.02
The evolving landscape of glioblastoma stem cells. Curr Opin Neurol (2013) 1.02
The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol (2008) 1.01
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99
Chemokine CXCL12 in neurodegenerative diseases: an SOS signal for stem cell-based repair. Trends Neurosci (2012) 0.99
Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res (2013) 0.99
The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion. Mol Cancer Ther (2007) 0.98
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol (2008) 0.96
New approaches to primary brain tumor treatment. Anticancer Drugs (2006) 0.96
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) (2006) 0.96
Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. Trends Neurosci (2009) 0.95
Twisted tango: brain tumor neurovascular interactions. Nat Neurosci (2011) 0.95
Notch signaling in cancer stem cells. Adv Exp Med Biol (2012) 0.95
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res (2006) 0.95
NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem (2009) 0.95
Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci (2005) 0.95
Medical oncology: treatment and management of malignant gliomas. Nat Rev Clin Oncol (2010) 0.94
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest (2014) 0.93
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev (2011) 0.92
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol (2004) 0.91
Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol (2010) 0.91
Cancer stem cell-specific scavenger receptor 36 drives glioblastoma progression. Stem Cells (2014) 0.89
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol (2012) 0.89
Endothelial expression of TNF receptor-1 generates a proapoptotic signal inhibited by integrin α6β1 in glioblastoma. Cancer Res (2012) 0.88
Antiangiogenic therapy in malignant glioma: promise and challenge. Curr Pharm Des (2007) 0.88
Glioma development: where did it all go wrong? Cell (2011) 0.88
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res (2009) 0.87